EUCTR2012-003661-17-GB进行中（未招募）1 期
A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patients with refractory diabetic macular oedema. - OZDRY
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subjects of either sex aged 18 years or over
- •2. Diagnosis of diabetes mellitus (type 1 or type 2). Any one of the following will be considere to be sufficient evidence that diabetes is present:
- •i. Current regular use of insulin for the treatment of diabetes
- •ii. Current regular use of oral anti-hyperglycaemic agents for the treatment of diabetes
- •iii. Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for Diagnosis of Diabetes)
- •3.Best corrected visual acuity in the study eye between =34 and =73 ETDRS letters at 1m at baseline attributable to DMO.
- •4.On clinical exam at baseline in the study eye, retinal thickening due to diabetic macular oedema involving the centre of the macula and OCT central subfield > 300 microns (Spectralis) despite previous therapy.
- •5. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs.
- •6. Ability to return for study visits
- •7. Visual acuity in fellow eye = 2/60
- •8. Ability to give informed consent throughout the duration of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •The following exclusions apply to the study eye only (i.e. they may be present for the non study eye, provided that inclusion criterion 8 is met):
- •1.Macular ischaemia (FAZ > 1000µm in diameter or severe perifoveal intercapillary loss on IVFA).
- •2.Macular oedema is considered to be due to a cause other than diabetic macular oedema. An eye should not be considered eligible if: (1) the macular oedema is considered to be related to cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities disease (e.g., a taut posterior hyaloid or epiretinal embrane) is the primary cause of the macular oedema.
- •3.Co-existent ocular disease: An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular oedema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non retinal conditions, such as amblyopia).
- •4.An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular oedema or alter visual acuity during the course of the study (e.g. vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, etc).
- •5.A substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 6/12 or worse if eye was otherwise normal).
- •6.History of treatment for DMO with peribulbar or intravitreal steroids in the study eye in the past 6 months.
- •7. History of macular laser in study eye in the last 3 months.
- •8. History of antiVEGF therapy within the last 1 month.
- •9. Active proliferative diabetic retinopathy or rubeosis in the study eye at baseline. (Stable and treated proliferative diabetic retinopathy may be included).
- •10. A condition that, in the opinion of the investigator, would preclude participation in the study.
- •11. A past medical history of significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant
- •12.. Major surgery within 28 days prior to randomisation or major surgery planned during the next 12 months at baseline. Major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter.
- •13. Participation in an investigational trial within 30 days of randomisation that involved treatment with any drug that has not received regulatory approval at the time of study entry. Note: subjects cannot receive another investigational drug while participating in the study.
- •14. Pregnant or lactating women or women intending to become pregnant within the study period.
- •15. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 3 months or anticipated within the next 6 months following randomisation.
- •16. Aphakia
- •17. A diagnosis of glaucoma which in the opinion of a glaucoma specialist is at high risk of progression or ocular hypertension requiring at least one topical medication.
研究者
相似试验
已完成
2 期
Biological E’s Polio vaccine clinical study for protection against Polio disease in 6-8 weeks old infants.CTRI/2023/08/055993Biological E.Limited120
招募中
4 期
Comparative study of effect of Remogliflozin and Empagliflozin on parameters of heart failure.CTRI/2020/11/029176Sengupta Hospital and Research Institute
进行中（未招募）
3 期
Efficacy and safety of masitinib to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanomaCTRI/2014/10/005095AB Science
进行中（未招募）
1 期
A randomised trial with breast cancer and lymphoma patients to test if medication can prevent cardiac damage caused by anthracycline chemotherapy.Myocardial toxicity and the development of left ventricular systolic dysfunctionMedDRA version: 20.1Level: LLTClassification code 10007612Term: Cardiac troponin I increasedSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10069501Term: Left ventricular systolic dysfunctionSystem Organ Class: 100000004849EUCTR2017-000896-99-GBniversity of Edinburgh175
Unknown
3 期
A prospective open label, randomized, multi-centre, parallel design, controlled study to evaluate the efficacy and safety of DNANOPAURONA to treating castration resistant prostate cancerCTRI/2018/05/013553Dhanvantari Nano Ayushadi Private Limited